|Neuren Pharmaceuticals Limited -- USA Stock|| |
USD 2.35 0.03 1.26%
CEO, Managing Director
Mr. Larry Glass was Chief Science Officer and Executive Director of Neuren Pharmaceuticals Limited since September 2, 2013. He is a seasoned manager with more than 30 years in the life sciences industry. Before he joined Neuren, he worked as an independent consultant for a number of biotech companies in the US and internationally, providing management, strategic and business development services. Prior to that, he was CEO of a contract research organisation that provided preclinical research and clinical trials support for major pharmaceutical and biotechnology companies and the US government. For a number of years, the CRO operated as a subsidiary of a NYSElisted company and was subsequently sold to a European biopharmaceutical enterprise which was then acquired by Johnson Johnson.
CEO Since 2013
61 3 9092 0480 http://www.neurenpharma.com
The company has return on total asset (ROA)
of (34.89) %
which means that it has lost $34.89 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (18.93) %
meaning that it generated substantial loss on money invested by shareholders.
Neuren Pharmaceuticals Limited, a biopharmaceutical company, focuses on the development of therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Port Melbourne, Australia. Neuren Pharmaceuticals is traded on OTC Market in USA.Neuren Pharmaceuticals Limited (NURPF) is traded on OTC Market in USA. It is located in 435 Williamstown Road and employs 10 people.